NR 568 ADVANCED PHARMACOLOGY EXAM / APPROVED NR 568
ADVANCED PHARMACOLOGY FINAL EXAM ACTUAL 2026/2027
TEST BANK PRACTICE QUESTIONS AND STUDY GUIDE
ACCURATE EXAM COMPLETE APPROVED QUESTIONS WITH
WELL ELABORATED SOLUTIONS AND DETAILED RATIONALES
(100% CORRECT VERIFIED ANSWERS) CURRENTLY UPDATED
VERSION 2026 EDITION |GUARANTEED SUCCESS A+ |INSTANT
DOWNLOAD PDF |JUST RELEASED
1. A 70-year-old patient with heart failure is started on digoxin.
Which age-related change in pharmacokinetics most increases the
risk of toxicity?
A. Increased hepatic first-pass metabolism
B. Increased volume of distribution for water-soluble drugs
C. Enhanced glomerular filtration rate
D. Decreased renal clearance of digoxin
Correct Answer: D
Rationale: Renal clearance declines with age, reducing digoxin
elimination. Dose adjustment based on renal function and
monitoring of digoxin levels is essential in older adults to prevent
toxicity.
,2. A patient with a genetic polymorphism resulting in CYP2D6 poor
metabolizer phenotype is prescribed codeine for pain. What is the
most likely outcome?
A. Little to no analgesic effect due to inability to convert codeine to
morphine
B. Increased risk of respiratory depression from rapid conversion to
morphine
C. Prolonged half-life of codeine but normal analgesia
D. Increased risk of serotonin syndrome
Correct Answer: A
Rationale: Codeine is a prodrug requiring CYP2D6 to convert to
its active metabolite, morphine. Poor metabolizers have reduced
analgesia because they cannot adequately convert codeine to
morphine.
3. A patient is receiving a drug that is a weak base (pKa 8.5). Which
of the following would increase its renal excretion?
A. Alkalinizing the urine (increasing pH)
B. Acidifying the urine (decreasing pH)
,C. Increasing urine flow rate only
D. Decreasing urine flow rate
Correct Answer: B
Rationale: Weak bases are ionized (and less reabsorbed) in acidic
urine. Acidification traps the drug in the urine, enhancing
excretion.
4. A patient with hepatic cirrhosis has a reduced ability to metabolize
drugs via phase I reactions. Which drug would be most affected?
A. Lorazepam (primarily phase II glucuronidation)
B. Phenytoin (primarily phase I oxidation)
C. Acetaminophen at therapeutic doses (phase II)
D. Morphine (phase II)
Correct Answer: B
Rationale: Phenytoin undergoes extensive hepatic oxidation via
CYP450 enzymes. Cirrhosis impairs phase I reactions more than
phase II, leading to drug accumulation and toxicity.
, 5. A patient is started on a drug with a narrow therapeutic index.
The nurse practitioner orders therapeutic drug monitoring. Which
principle best justifies this?
A. Small changes in dose or clearance can lead to toxicity or
treatment failure
B. All drugs require monitoring regardless of index
C. The drug has a wide safety margin
D. Monitoring is only needed for intravenous drugs
Correct Answer: A
Rationale: Narrow therapeutic index drugs (e.g., warfarin,
phenytoin, digoxin) have small margins between efficacy and
toxicity, requiring therapeutic drug monitoring to ensure safe and
effective dosing.
6. A patient is taking a drug that is a substrate of P-glycoprotein (P-
gp). Which co-administered drug could increase the oral
bioavailability of this substrate?
A. A P-gp inhibitor (e.g., verapamil)
ADVANCED PHARMACOLOGY FINAL EXAM ACTUAL 2026/2027
TEST BANK PRACTICE QUESTIONS AND STUDY GUIDE
ACCURATE EXAM COMPLETE APPROVED QUESTIONS WITH
WELL ELABORATED SOLUTIONS AND DETAILED RATIONALES
(100% CORRECT VERIFIED ANSWERS) CURRENTLY UPDATED
VERSION 2026 EDITION |GUARANTEED SUCCESS A+ |INSTANT
DOWNLOAD PDF |JUST RELEASED
1. A 70-year-old patient with heart failure is started on digoxin.
Which age-related change in pharmacokinetics most increases the
risk of toxicity?
A. Increased hepatic first-pass metabolism
B. Increased volume of distribution for water-soluble drugs
C. Enhanced glomerular filtration rate
D. Decreased renal clearance of digoxin
Correct Answer: D
Rationale: Renal clearance declines with age, reducing digoxin
elimination. Dose adjustment based on renal function and
monitoring of digoxin levels is essential in older adults to prevent
toxicity.
,2. A patient with a genetic polymorphism resulting in CYP2D6 poor
metabolizer phenotype is prescribed codeine for pain. What is the
most likely outcome?
A. Little to no analgesic effect due to inability to convert codeine to
morphine
B. Increased risk of respiratory depression from rapid conversion to
morphine
C. Prolonged half-life of codeine but normal analgesia
D. Increased risk of serotonin syndrome
Correct Answer: A
Rationale: Codeine is a prodrug requiring CYP2D6 to convert to
its active metabolite, morphine. Poor metabolizers have reduced
analgesia because they cannot adequately convert codeine to
morphine.
3. A patient is receiving a drug that is a weak base (pKa 8.5). Which
of the following would increase its renal excretion?
A. Alkalinizing the urine (increasing pH)
B. Acidifying the urine (decreasing pH)
,C. Increasing urine flow rate only
D. Decreasing urine flow rate
Correct Answer: B
Rationale: Weak bases are ionized (and less reabsorbed) in acidic
urine. Acidification traps the drug in the urine, enhancing
excretion.
4. A patient with hepatic cirrhosis has a reduced ability to metabolize
drugs via phase I reactions. Which drug would be most affected?
A. Lorazepam (primarily phase II glucuronidation)
B. Phenytoin (primarily phase I oxidation)
C. Acetaminophen at therapeutic doses (phase II)
D. Morphine (phase II)
Correct Answer: B
Rationale: Phenytoin undergoes extensive hepatic oxidation via
CYP450 enzymes. Cirrhosis impairs phase I reactions more than
phase II, leading to drug accumulation and toxicity.
, 5. A patient is started on a drug with a narrow therapeutic index.
The nurse practitioner orders therapeutic drug monitoring. Which
principle best justifies this?
A. Small changes in dose or clearance can lead to toxicity or
treatment failure
B. All drugs require monitoring regardless of index
C. The drug has a wide safety margin
D. Monitoring is only needed for intravenous drugs
Correct Answer: A
Rationale: Narrow therapeutic index drugs (e.g., warfarin,
phenytoin, digoxin) have small margins between efficacy and
toxicity, requiring therapeutic drug monitoring to ensure safe and
effective dosing.
6. A patient is taking a drug that is a substrate of P-glycoprotein (P-
gp). Which co-administered drug could increase the oral
bioavailability of this substrate?
A. A P-gp inhibitor (e.g., verapamil)
